H. Kimura

发表

Multicenter Study of Pegylated Interferon α‐2a Monotherapy for Hepatitis C Virus‐Infected Patients on Hemodialysis: REACH Study

N. Hotta, N. Izumi, K. Nitta, 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy

M. Kurosaki, N. Izumi, Y. Osaki, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study

M. Kurosaki, N. Izumi, Shinichiro Nakamura, 2022, Cancers.

Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group

M. Kurosaki, N. Izumi, T. Sohda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.

M. Kurosaki, N. Izumi, H. Marusawa, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

M. Kurosaki, N. Izumi, T. Sohda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis

M. Kurosaki, N. Izumi, T. Sohda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus

M. Kurosaki, N. Izumi, H. Marusawa, 2021, Hepatology communications.

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score

M. Kurosaki, N. Izumi, H. Marusawa, 2020, Scientific Reports.

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection

M. Kurosaki, N. Izumi, H. Marusawa, 2022, JGH open : an open access journal of gastroenterology and hepatology.

Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group

M. Kurosaki, N. Izumi, S. Tsuruta, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group

M. Kurosaki, N. Izumi, T. Sohda, 2018, PloS one.

Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group

M. Kurosaki, N. Izumi, T. Sohda, 2018, Journal of Gastroenterology.

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response

M. Kurosaki, N. Izumi, H. Marusawa, 2021, JGH open : an open access journal of gastroenterology and hepatology.

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study

M. Kurosaki, N. Izumi, T. Sohda, 2021, Cancers.

Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

M. Kurosaki, N. Izumi, H. Marusawa, 2021, Journal of medical virology.

Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen

M. Kurosaki, N. Izumi, T. Sohda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatitis B surface antigen reduction by switching from long‐term nucleoside/nucleotide analogue administration to pegylated interferon

M. Kurosaki, N. Izumi, Y. Asahina, 2017, Journal of viral hepatitis.

Hepatitis B Surface Antigen Reduction by Switching from Long-term Nucleoside/nucleotide Analog Administration to Pegylated Interferon Short running title: Sequential PEG-IFN after long-term NA

M. Kurosaki, N. Izumi, Y. Asahina, 2017 .

The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan.

M. Kurosaki, N. Izumi, T. Sohda, 2019, Journal of Clinical Oncology.